Núñez, Olivier; Olmedo, Carmen; Moreno-Pérez, David; Lorusso, Nicola; Fernández-Martínez, Sergio; Pastor-Villalba, Pedro-Eliseo; Gutiérrez, Ángeles; García, Marcos-Alonso; Latasa, Pello; Sancho, Rosa; Mendioroz, Jacobo; Martínez-Marcos, Montserrat; Muñoz-Platon, Enrique; García-Rivera, María-Victoria; Pérez-Martínez, Olaia; Álvarez-Gil, Rosa; Wagner, Eva-Rivas; López-González-Coviella, Nieves; Zornoza-Moreno, Matilde; Barranco-Boada, María-Isabel; Pacheco, M-del-Carmen; Álvarez-Río, Virginia; Jaume, Miguel-Fiol; Arance, Roxana-Morey; Sancho, Begoña-Adiego; Méndez-Díaz, Manuel; Batalla-Rebollo, Noa; Andreu, Cristina; Castilla, Jesús; García-Cenoz, Manuel; Fernández-Ibáñez, Ana; Huerta-Huerta, Marta; Ibáñez-Pérez, Ana-Carmen; Berradre-Saenz, Belén; Lamas, Joaquín; Hermoso, Luisa; Casado-Cobo, Susana; Galán-Cuesta, Manuel; Montenegro, Sara; Domínguez, María; Jarrin, Inmaculada; Limia, Aurora; Pastor-Barriuso, Roberto; Monge, Susana
(EUR CENTRE DIS PREVENTION & CONTROL, 2025-02-06)
BackgroundRespiratory syncytial virus (RSV) causes substantial morbidity in infants < 1 year. In October 2023, Spain recommended the monoclonal antibody nirsevimab to all children born since 1 April 2023, at birth or as ...